ALDX
Aldeyra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.66
−3.58%Sep 29, 2026, 18:34 UTC
Aldeyra Therapeutics announced its intent to submit a formal dispute resolution request with the FDA regarding its reproxalap program after an FDA rejection.
Source:Sep 28, 2026, 20:30 UTC
Aldeyra Therapeutics announced it will host a regulatory update webcast on September 29, 2026, focused on its investigational dry eye disease drug reproxalap.
Source:Jun 10, 2026, 00:00 UTC
Aldeyra Therapeutics, Inc. elected Todd C. Brady, M.D., Ph.D. as a Class III director and appointed Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, effective June 9, 2026.
Jun 5, 2026, 01:02 UTC
Aldeyra Therapeutics expects near-term FDA feedback on its dry eye disease candidate reproxalap after receiving a third complete response letter.
Source: